Last night, Faron announced last night that he would carry out a targeted issue to be conducted by way of an accelerated book-building. The company was aiming for a capital raise of around 10 MEUR, but with a 1.8-fold oversubscription, the company will upsize the issue and raise gross proceeds of 12 MEUR (before expenses).

Faron announced that it has identified the last patient for the Phase II BEXMAB study and now expects the topline readout in April. As a result, patient enrollment was completed in January as previously announced, although the topline response rate readout was bumped slightly forward from the end of Q1'25 as previously announced.

Faron reported more detailed interim results of the BEXMAB study at the annual meeting of the American Society of Hematology (ASH). The company is on track for the important final read-out in March, as tolerability and overall response rate have remained at good levels.

Faron announced on Monday that it has been awarded an Innovation Passport for the treatment of relapsed/refractory myelodysplastic syndrome (r/r MDS).